Drug Screen Panel 9, Meconium [30427X]

All positive screens will have a quantitative confirmation performed at an additional charge. CPT coding varies by drugs confirmed.

SRHC Clients:

• Meconium sample ( at least 1 gram)
• Multiple samples may be collected to obtain minimum amount

LAB479

30427

Amphetamines, Barbiturates, Benzodiazepines, Cocaine metabolites, Marijuana Metabolite, Methadone, Opiates, PCP (Phencyclidine), Propoxyphene

5 gram fresh meconium collected in a sterile plastic leak-proof container

1 g

Refrigerated, stable 7 day
Frozen, stable 30 days

Room temperature: 48 hours
Refrigerated: 7 days
Frozen: 30 days

Sample soaked into diaper lining.

Set up: Daily; Report available: Next day

See Laboratory Report

Meconium contains the amniotic fluid swallowed by the fetus in the last half of pregnancy and is released as the first stools after birth. Meconium is easier to collect than neonatal urine and provides a much longer window of exposure of up to 20 weeks. Meconium is an effective biological marker of in-utero drug exposure, and can provide insights leading to improved neonatal outcomes, as well as provide evidence to ensure appropriate rehabilitation of mothers suffering from addiction. The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive mass spectroscopy (MS) methodology. Test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the amount of drug that the neonate was exposed to.